Bleichmar Fonti & Auld LLP is investigating Select Medical Holdings Corporation's board and senior management for potential breaches of fiduciary duties related to the pending acquisition at $16.50 per share. The deal, announced on March 2, 2026, involves a consortium led by co-founder Robert A. Ortenzio, executive Martin F. Jackson, and private equity firm Welsh, Carson, Anderson & Stowe, which has ties to director Russel L. Carson. Public shareholders would receive $16.50 per share in cash, while Ortenzio, Jackson, and certain affiliates are permitted to roll over their holdings into the post-merger company, an option not available to other stockholders. The stockholder vote is scheduled for June 26, 2026, and the merger could close shortly thereafter, potentially limiting further investigation into its fairness.
Select Medical HoldingsInvestigation into potential breaches of fiduciary duties related to the acquisition, which may lead to legal challenges or delays.